Brivekimig Trial for Hidradenitis Suppurativa
Phase 2
188
about 2.5 years
18+
11 sites in CA, FL, GA +6
What this study is about
This trial is testing a treatment called brivekimig in people with moderate to severe hidradenitis suppurativa. The goal is to see if brivekimig helps treat HS and how safe it is.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Brivekimig
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: Change from Baseline in Dermatology Life Quality Index (DLQI) total score at Week 16., Change from Baseline in Hidradenitis Suppurativa Quality of Life (HiSQOL) total score at Week 16., Change from Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) at Week 16, Change from Baseline in draining tunnel count at Week 16., Number of participants with treatment-emergent adverse events (TEAE), serious adverse events (SAE) and laboratory anomalies., Percentage of participants achieving response on the Hidradenitis Suppurativa Skin Pain Numeric Rating Scale from the HS Symptom Assessment Questionnaire (HS-SAQ skin pain NRS) at week 8